Alpharma movements into China with Tongde Pharmaceutical acquisition Alpharma Inc.

Following the acquisition, the business will continue to support the existing customer bottom of Tongde while also exporting the merchandise to other markets This agreement establishes a second footprint for Alpharma in the important Chinese market , commented Dean Mitchell, Chief and President Executive Officer. In 2006, we announced an contract with Zhejiang Hisun Pharmaceutical Co., Ltd that will double the capacity of the business’s largest and fastest developing Active Pharmaceutical Ingredient product, vancomycin, subject to the receipt of the required regulatory approvals.Additional results showed these mice had been protected from muscle tissue fiber deterioration, that these were better performers in home treadmill tests, that they had very much reduced levels of renal sclerosis, intestinal fibrosis and tubular atrophy – – all signs of aging. They also showed higher cardiac-stress tolerance and level of resistance to age-related retinal atrophy. Co-author Darren Baker, Ph.D., of Mayo Clinic, says the results present BubR1 and its connected regulators are promising targets for a wide spectrum of aneuploid human cancers and important age-related disorders that dictate human health. .

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson’s disease Ceregene, Inc., a biopharmaceutical company, today that enrollment is normally proceeding in a fresh Phase 1/2 scientific study evaluating CERE-120 announced, a gene therapy product which delivers the neurotrophic element neurturin, to dying neurons in Parkinson’s disease individuals.